File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design

TitleCabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design
Authors
Keywordsatezolizumab
cabozantinib
hepatocellular carcinoma
Issue Date2020
PublisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/fon
Citation
Future Oncology, 2020, v. 16 n. 21, p. 1525-1536 How to Cite?
AbstractCabozantinib is an oral tyrosine kinase inhibitor that targets VEGFR, MET and the TAM (TYRO3, AXL, MER) family of kinase receptors. In addition to their role in tumor growth and angiogenesis, cabozantinib targets promote an immune-suppressive microenvironment. Cabozantinib is approved as single-agent therapy for patients with advanced hepatocellular carcinoma who received prior sorafenib. Owing to its antitumor and immunomodulatory properties, cabozantinib is being developed in combination with immune checkpoint inhibitors. Early studies of these combinations have shown promising antitumor activity and tolerability in patients with solid tumors. Here, we describe the rationale and design of COSMIC-312, a Phase III study evaluating the safety and efficacy of cabozantinib in combination with atezolizumab (anti–PD-L1 monoclonal antibody) versus sorafenib for treatment-naive patients with advanced hepatocellular carcinoma. Clinical Trial Registration: NCT03755791
Persistent Identifierhttp://hdl.handle.net/10722/279464
ISSN
2020 Impact Factor: 3.404
2020 SCImago Journal Rankings: 0.857
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKelley, RK-
dc.contributor.authorOliver, JW-
dc.contributor.authorHazra, S-
dc.contributor.authorBenzaghou, Fawzi-
dc.contributor.authorYau, T-
dc.contributor.authorCheng, AL-
dc.contributor.authorRimassa, L-
dc.date.accessioned2019-11-01T07:17:52Z-
dc.date.available2019-11-01T07:17:52Z-
dc.date.issued2020-
dc.identifier.citationFuture Oncology, 2020, v. 16 n. 21, p. 1525-1536-
dc.identifier.issn1479-6694-
dc.identifier.urihttp://hdl.handle.net/10722/279464-
dc.description.abstractCabozantinib is an oral tyrosine kinase inhibitor that targets VEGFR, MET and the TAM (TYRO3, AXL, MER) family of kinase receptors. In addition to their role in tumor growth and angiogenesis, cabozantinib targets promote an immune-suppressive microenvironment. Cabozantinib is approved as single-agent therapy for patients with advanced hepatocellular carcinoma who received prior sorafenib. Owing to its antitumor and immunomodulatory properties, cabozantinib is being developed in combination with immune checkpoint inhibitors. Early studies of these combinations have shown promising antitumor activity and tolerability in patients with solid tumors. Here, we describe the rationale and design of COSMIC-312, a Phase III study evaluating the safety and efficacy of cabozantinib in combination with atezolizumab (anti–PD-L1 monoclonal antibody) versus sorafenib for treatment-naive patients with advanced hepatocellular carcinoma. Clinical Trial Registration: NCT03755791-
dc.languageeng-
dc.publisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/fon-
dc.relation.ispartofFuture Oncology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectatezolizumab-
dc.subjectcabozantinib-
dc.subjecthepatocellular carcinoma-
dc.titleCabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design-
dc.typeArticle-
dc.identifier.emailYau, T: tyaucc@hku.hk-
dc.identifier.authorityYau, T=rp01466-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.2217/fon-2020-0283-
dc.identifier.pmid32491932-
dc.identifier.scopuseid_2-s2.0-85088251242-
dc.identifier.hkuros308507-
dc.identifier.volume16-
dc.identifier.issue21-
dc.identifier.spage1525-
dc.identifier.epage1536-
dc.identifier.isiWOS:000551534300005-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1479-6694-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats